SCHEMBL21292981

SCHEMBL21292981

Cc1nccc(-c2ccc3nc(Cl)ccc3c2)c1C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 4/20 0.39
▸ CTSD P07339 1/20 0.39
▸ AR P10275 1/20 0.38
▸ NTRK1 P04629 2/20 0.38
▸ PIM1 P11309 2/20 0.38
▸ ACVR1 Q04771 1/20 0.38
▸ HPGD P15428 1/20 0.37
▸ NMT1 P30419 1/20 0.37
▸ MKNK1 Q9BUB5 1/20 0.36
▸ MKNK2 Q9HBH9 1/20 0.36
▸ MTOR P42345 5/20 0.36
▸ SRC P12931 2/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ HCK P08631 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16487127 0.88 SYK (0.43) BACE1CTSDARNTRK1PIM1
SCHEMBL17909883 0.81 SYK (0.38) BACE1ARHPGDNMT1MKNK1
SCHEMBL21292979 0.81 SRC (0.40) BACE1CTSDARNTRK1PIM1
SCHEMBL18425047 0.77 KMO (0.40) BACE1CTSDACVR1HPGDMTOR
SCHEMBL17909879 0.76 SRC (0.40) BACE1ARHPGDMKNK1MKNK2
SCHEMBL21292970 0.76 HPGD (0.39) BACE1CTSDARHPGDMTOR
SCHEMBL21292982 0.76 HPGD (0.48) BACE1HPGDNMT1MTORSRC
SCHEMBL20767113 0.72 MKNK1 (0.51) NTRK1PIM1ACVR1MKNK1MKNK2
SCHEMBL18425042 0.72 KMO (0.39) BACE1CTSDHPGDMTORSRC
SCHEMBL17909778 0.72 KDM4E (0.38) BACE1CTSDHPGDNMT1MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10981893-B2 Therapeutic inhibitory compounds ATTUNE PHARMACEUTICALS, INC. (US) 2021-04-20 — — US disclosed
US-20190263783-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2019-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981893-B2 Therapeutic inhibitory compounds SERPINB1, KLKB1, SERPINE1 BACE1 1653/4885CTSD 309/4885AR 3635/4885
US-20190263783-A1 THERAPEUTIC INHIBITORY COMPOUNDS SERPINB1, KLKB1, SERPINE1 BACE1 1104/4885CTSD 156/4885AR 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback